History of Changes for Study: NCT06036199

Focused Ultrasound Pallidotomy for Dyskinetic Cerebral Palsy in Pediatric and Young Adult Subjects

A study version is represented by a row in the table.
Select two study versions to compare. One each from columns A and B.
Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
Click "Compare" to do the comparison and show the differences.
Select a version's Submitted Date link to see a rendering of the study for that version.
The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
Hover over the "Recruitment Status" to see how the study's recruitment status changed.
Study edits or deletions are displayed in red.
Study additions are displayed in green.

Study Record Versions

Version	A	B	Submitted Date	Changes
1			September 12, 2023	None (earliest Version on record)
2			February 8, 2024	Recruitment Status, Study Status, Contacts/Locations and Oversight

Comparison Format:

Merged
Side-by-Side

Study Identification


Unique Protocol ID:	G230044
Brief Title:	Focused Ultrasound Pallidotomy for Dyskinetic Cerebral Palsy in Pediatric and Young Adult Subjects
Official Title:	Safety and Impact on Quality of Life of Focused Ultrasound Pallidotomy for Dyskinetic Cerebral Palsy in Pediatric and Young Adult Subjects
Secondary IDs:

Study Status


Record Verification:	September 2023
Overall Status:	Not yet recruiting
Study Start:	September 2023
Primary Completion:	August 2025 [Anticipated]
Study Completion:	August 2025 [Anticipated]

First Submitted:	May 2, 2023
First Submitted that Met QC Criteria:	September 12, 2023
First Posted:	September 13, 2023 [Actual]

Last Update Submitted that Met QC Criteria:	September 12, 2023
Last Update Posted:	September 13, 2023 [Actual]

Sponsor/Collaborators


Sponsor:	Children's National Research Institute
Responsible Party:	Principal Investigator Investigator: Chima Oluigbo Official Title: Principal Investigator and Sponsor Affiliation: Children's National Research Institute
Collaborators:

Oversight


U.S. FDA-regulated Drug:	No
U.S. FDA-regulated Device:	Yes
Unapproved/Uncleared Device:
Pediatric Postmarket Surveillance:
Data Monitoring:	Yes

Study Description

Brief Summary:

The primary objective of the proposed study is to evaluate the safety of ExAblate Transcranial MRgFUS as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy

Detailed Description:

The secondary is to assess the impact on Quality of Life of Focused Ultrasound Bilateral and unilateral Pallidotomy for Dyskinetic Cerebral Palsy in Pediatric and Young Adult Subjects. In addition, the impact of bilateral pallidotomy on motor development, pain perception, speech, memory, attention and cognition in these patients will also be assessed.

Conditions


Conditions:	Cerebral Palsy, Dyskinetic Secondary Dystonia
Keywords:	High intensity focused ultrasound (HIFU) Pallidotomy

Study Design


Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Not Applicable
Interventional Study Model:	Single Group Assignment
Number of Arms:	1
Masking:	None (Open Label)
Allocation:	N/A
Enrollment:	10 [Anticipated]

Arms and Interventions

Arms	Assigned Interventions
Experimental: Focused Ultrasound Pallidotomy Pediatric and young adult patients between ages of 8 and 22 years with pharmaco-resistant secondary dystonia due to dyskinetic cerebral palsy who have Focused Ultrasound Pallidotomy	Device: Focused Ultrasound Pallidotomy Use of ExAblate Transcranial MR guided Focused Ultrasound as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy

Outcome Measures


Primary Outcome Measures:
1.	Incidence and severity of device-related and procedure-related adverse events (AE) [ Time Frame: 2 years ] Safety will be determined by an evaluation of the incidence and severity of device-related and procedure-related adverse events (AE) from the first treatment day visit through the 24-month post-treatment time point. All AEs will be reported and categorized as related to the device versus the ablation procedure.
Secondary Outcome Measures:
1.	Burke-Fahn-Marsden-Dystonia Rating Scale movement and disability [ Time Frame: 2 years ] Assessment of speech and swallowing. Score range: 0-30, 0 indicates complete independence, 30 indicates complete dependence.
2.	Family Scale (FaBel) [ Time Frame: 2 years ] Assessment of the burden for caregivers. Score range: 0-84, 0 indicates no burden, 84 indicates very severe burden.
3.	Canadian Occupational Performance Measure (COPM) [ Time Frame: 2 years ] Assessment of activities of daily living.
4.	Gross Motor Function Measure (GMFM-66) [ Time Frame: 2 years ] Assessment of physical disability. Score range: 0-3, 0 indicates no performance, 3 indicates complete performance.
5.	Gross Motor Function Classification System (GMFCS) [ Time Frame: 2 years ] Degree of physical impairment. Score range: 1-5, 1 indicates no limitations, 5 indicates severe limitations.
6.	SF-36 for assessment of quality of life [ Time Frame: 2 years ] Assessment of quality of life of subject. Score range: 0-100, 0 indicates bad health state, 100 indicates an excellent health state.
7.	Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD) [ Time Frame: 2 years ] Assessment of Quality of life of Caregivers and Subject. Score range: 0-100, 0 indicates a bad score, 100 indicates an excellent score.
8.	Frenchay Dysarthria Assessment [ Time Frame: 2 years ] Assessment of speech and swallowing. Score range:
9.	Assessment of Cognition [ Time Frame: 2 years ] Snijders-Oomen-Non-Verbal-Intelligence Test (SON-R)
10.	Strengths and Difficulties Questionnaire [ Time Frame: 2 years ] Assessment of mood and attention. Score range: 0-40, 0 indicates normal, 40 indicates abnormal.
11.	Assessment of Attention [ Time Frame: 2 years ] Attentional Network Test (ANT)
12.	Assessment of cognition [ Time Frame: 2 years ] Non-Verbal-Learning Test (NVLT)
13.	Wong Baker Faces [ Time Frame: 2 years ] Assessment of pain. Score range; 0-10, 0 indicates no pain, 10 indicates worst pain.
14.	Tardieu Scale [ Time Frame: 2 years ] Assessment of the severity of spasticity. Score range: 0-5, 0 indicates no resistance, 5 indicates no movement.
15.	Dyskinesia Impairment Scale (DIS) [ Time Frame: 2 years ] Assessment of the severity of chorea and dystonia. Score range: 0-576, 0 indicates no dystonia, 576 indicates very severe dystonia.
16.	Barry Albright Dystonia Scale [ Time Frame: 2 years ] Score range: 0-32, 0 indicates no dystonia, 32 indicates severe dystonia.

Eligibility


Minimum Age:	8 Years
Maximum Age:	22 Years
Sex:	All
Gender Based:
Accepts Healthy Volunteers:	No
Criteria:	Inclusion Criteria: The treating physician has chosen GPi-DBS or pallidotomy for the treatment of the secondary dystonia caused by cerebral palsy in this patient Patient and/or legal representative, if the patient is underaged or not capable to give consent himself, have chosen pallidotomy as treatment The consent to participate in the trial of the underaged patient, if he is capable to understand the study requirements, is required Age at enrolment 8-22 years Diagnosis of secondary dystonia due to cerebral palsy caused by perinatal hypoxic injury Anti-dystonic pharmacotherapy insufficient Stable anti-dystonic medication over the last 30 days Globus pallidus internus (pars posterior) and thalamus (motor part) intact on MRI (not older than 2 years - if possible) No fixed severe skeletal deformations with loss of function, which need immediate orthopaedic surgical intervention Sufficient compliance of the patient or the legal representative if the patient is underaged or not capable to give consent himself to take part in the study Informed consent to take part in the study from patient and/or legal representative if the patient is underaged or not capable to give consent himself Patient and/or legal representative if the patient is underaged or not capable to give consent himself, understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed Exclusion Criteria: Patients with known primary (e.g. DYT1) or idiopathic dystonia Severe axial hypotonia with total loss of head control (e.g. absence of control at "upper thoracic level" in the SATCo score) (medication effect excluded) Fixed hemi-dystonia Severe spasticity in knee- and elbow-flexors and -extensors (Modified Ashworth Scale >3) Fixed severe skeletal contractions with loss of function which require immediate orthopaedic surgical intervention Patients with other severe concurrent neurological disease (e. g. brain tumor, neurodegenerative diseases, trauma etc.) Condition likely to require use of MRI in the future Any intracranial abnormality or medical condition that would contraindicate DBS surgery Any findings in neuropsychological screening assessments that would contraindicate DBS surgery Any current drug and / or alcohol abuse Any history of frequent grand-mal seizures without response to anticonvulsive treatment Any other active implanted device (e.g. Cochlear implant, pacemaker), whether turned on or off, would be allowed provided that they do not interfere with functioning of the device. The presence of DBS leads due the risks of these ferromagnetic devices in the MRI environment. A history of neurostimulation intolerance in any area of the body. Currently on any anticoagulant medications that cannot be discontinued during perioperative period. Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival <24 months. Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days; any other trial participation should be approved by the Principal Investigator. A female that is breastfeeding or of childbearing potential with a positive urine pregnancy test or - if a person is sexually active - not using sufficient contraception with a Pearl Index of less than 1% including all forms of hormonal contraception ("antibaby-pill", hormonal plaster, NuvaRing®, Implanon®, hormonal depot injections, contraceptive coil), the tubal ligature (female sterilization). Alternatively, the female of child bearing potential is sexually abstinent. Subjects who have contraindications to anesthesia, in the judgment of the attending anesthesiologist Subjects who are unwilling or unable to undergo general anesthesia Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the subject or the quality of the data. Minimum head circumference < 49cm Skull Density Ratio (SDR) <0.40.

Contacts/Locations


Central Contact Person:	Chima Oluigbo, MD Telephone: 2024763531 Email: coluigbo@childrensnational.org
Central Contact Backup:	Saige Teti Telephone: 2024763755 Email: sateti@childrensnational.org
Study Officials:	Chima Oluigbo, MD Principal Investigator Children's National Hospital, Washington, DC
Locations:

IPDSharing


Plan to Share IPD:	No

References


Citations:
Links:
Available IPD/Information: